Regeneron is sliding today despite the company announcing an expansion of its long-standing alliance with Sanofi late yesterday evening.
This deal, valued at up to 8 billion dollars, adds four next-generation, long-acting immunology antibodies to their collaboration, including the clinical-stage candidate REGN20423. While the company also recently reported positive data showing its experimental drug trevogrumab reduces muscle loss when combined with sem